You just read:

FDA Approves Daiichi Sankyo's TURALIO™ (pexidartinib) for the Treatment of Select Patients with TGCT, a Rare and Debilitating Tumor

News provided by

Daiichi Sankyo Company, Limited

Aug 02, 2019, 19:40 ET